The interim results of a study designed by adding a plasmid encoding p62/SQSTM1 (a multi-domain protein that regulates inflammation, apoptosis, and autophagy) to the standard gemcitabine chemotherapy proved that it may be effective for patients with platinum-resistant ovarian cancer, resulting in a PFS of 5.7 months (compared to 2.4 months in the control group, p = 0.08) [47]. This evidence concerns the gene SQSTM1 and ovarian cancer.